Medicare Australia (the government healthcare system) was approached about use of Medicare rebates in the study and the response indicated that this would be acceptable for the clinical care component of the research. This enabled the treatment to be delivered in line with available rebates, which in turn provided good alignment with phase 2 translational research considerations of practicability of implementation in routine clinical work.